Parathyroid hormone analogues in the treatment of osteoporosis. - Wikidata - wikimedia - TriplyDB

Parathyroid hormone analogues in the treatment of osteoporosis.

Parathyroid hormone analogues in the treatment of osteoporosis.

http://www.wikidata.org/entity/Q37900475

about

Human parathyroid hormone for preventing and treating glucocorticoid-induced osteoporosis PTH receptor-1 signalling-mechanistic insights and therapeutic prospects The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials The influence of teriparatide in induced tooth movement: A systematic review Inflammation as a contributing factor among postmenopausal Saudi women with osteoporosis The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1-34 treatment.Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis.Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells.Sorting nexin 27 couples PTHR trafficking to retromer for signal regulation in osteoblasts during bone growth.Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.Causes, consequences, and treatment of osteoporosis in men.Effects of salvianolate on bone metabolism in glucocorticoid-treated lupus-prone B6.MRL-Fas (lpr) /J mice.Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.Clec11a/osteolectin is an osteogenic growth factor that promotes the maintenance of the adult skeleton.Causes, mechanisms and management of paediatric osteoporosis.Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature.Perioperative Medical Management of Spine Surgery Patients With Osteoporosis.CancerPDF: A repository of cancer-associated peptidome found in human biofluids.Short Anabolic Peptides for Bone Growth.Role of receptor activity modifying protein 1 in function of the calcium sensing receptor in the human TT thyroid carcinoma cell line.Endogenous parathyroid hormone and knee osteoarthritis: a cross-sectional study.Intermittent parathyroid hormone administration improves periodontal healing in rats.Effects of continual intermittent administration of parathyroid hormone on implant stability in the presence of osteoporosis: an in vivo study using resonance frequency analysis in a rabbit model.Synthesis and in vitro bone cell activity of analogues of the cyclohexapeptide dianthin G.Structure activity relationship study on the peptide hormone preptin, a novel bone-anabolic agent for the treatment of osteoporosis.

P2860

Q24194063-880FE2D5-8F10-419D-9174-820FFE7DB2E1 Q26798005-75E5B160-39B0-41AD-BED1-7770ACBF8193 Q27010303-411ED51D-E576-4456-BAFC-A6B9F5DEBFBB Q28067376-5DBCAE5B-CF18-481E-B025-5FF589B634D3 Q28817706-F6717ED1-EB68-4BB2-81D7-5CF66AC27DFB Q30486707-290970E1-DA85-41BB-8FA6-C875953FEDD9 Q33837110-4D2511E1-770F-4F7E-8938-3D96702A2696 Q33859459-07692306-DC0F-42B5-ACAD-B6C1A533F69F Q35017714-5D08A751-5581-4BD4-AD82-4EF715026BBC Q35087618-164E5692-BEE5-49E8-98C9-A5DE61068498 Q36004112-5B3D1DA3-9C17-42E8-B5C8-2965CFFF79E5 Q36236285-14BEFB98-104C-4655-B40F-4BE61D104018 Q36255855-F90CA0D1-0C99-48B9-A4A8-88F2AE2CC966 Q36358722-EAF33CA6-3687-4D6B-9D0C-2D99E8445DE8 Q36798625-ACCF0016-68C4-47BB-BA97-2B5790AF3396 Q36817240-77C71027-7438-4CB9-B240-D5A0FBAA2D53 Q37134718-0F02AFF7-1371-4A20-9EA7-E21D8E8609E2 Q37175331-E73B03EE-92F4-4551-A85D-54D64ACA10B3 Q37430684-D9F7D9EF-CD7D-4619-9928-68B744DACA84 Q37506244-D05660C9-BC4C-4F5D-9AC3-091D2520EE2C Q38099517-0B05C49D-20AD-48F9-9E42-7233777B3FD0 Q38429677-1D5BD324-553C-446F-AE79-D5094AF011B6 Q38588299-AF3A85B4-9EA4-4C70-B118-34BCF0E9959A Q38803215-BDA33CE3-22E0-4079-A7C0-C98A0A9BEFA9 Q38864194-8179FACD-A2D2-42F8-952B-E02B920A71A4 Q39031481-10D9FB42-0F53-481E-B9FB-CC6126C34C01 Q41065224-3B3CE521-CABB-4843-B1C5-94E7789CD01C Q43463995-E27B3CE7-2D71-4E6F-A720-0A7759A2754F Q47411007-CAAD2665-BC69-43A9-94A9-64EEBCA5BCEE Q53155600-5538595B-133E-4D37-BCDC-6BC99FE1E562 Q53755539-96CE6942-1A79-45B4-82F3-4045A5B025E6

P2860

Parathyroid hormone analogues in the treatment of osteoporosis.

http://www.wikidata.org/entity/Q37900475

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Parathyroid hormone analogues in the treatment of osteoporosis.

@en

Parathyroid hormone analogues in the treatment of osteoporosis.

@nl

type

label

Parathyroid hormone analogues in the treatment of osteoporosis.

@en

Parathyroid hormone analogues in the treatment of osteoporosis.

@nl

prefLabel

Parathyroid hormone analogues in the treatment of osteoporosis.

@en

Parathyroid hormone analogues in the treatment of osteoporosis.

@nl

P1433

Q37900475-63F2B2EE-E538-446B-81F1-CB13D1E7FF0B

P1476

Q37900475-E38D542D-42FF-4D53-A0D2-4A0EE23B1B6D

P2093

Q37900475-6220B7AE-BCDC-4C50-875A-F91204181C46

Q37900475-B31C26FA-BFD1-4C03-9370-46FBA9EF3266

P2860

Q37900475-0323DD1C-59B1-4C0B-B1E5-899E859704EA

Q37900475-09BB155D-9AAB-44D4-B366-A3CCF9CD8B9B

Q37900475-0A58D1AF-3BD8-4652-A72D-DAB64E8949BD

Q37900475-114EDFF8-11A0-4AF0-AF05-956A6C1B4DC0

Q37900475-165C50E3-FE9D-4D51-86D0-7EBE81DCDC35

Q37900475-18D247ED-ADC9-4B64-8279-34FA9E75E650

Q37900475-22CF24B4-6179-4648-B00E-4B0707DAEEAF

Q37900475-24F2D26D-B2F8-4CAC-9E1D-AF097ADEF208

Q37900475-28A34868-B9D7-4B8A-8345-F0336EB3F330

Q37900475-28E8D020-91A5-40FC-8282-EF8F66CA7EB5

P2888

Q37900475-79D743A3-8C38-4A36-9E86-E1E11D67F11D

P304

Q37900475-CFB23C0C-03AB-40D9-8DED-1B775BF6A325

P31

Q37900475-CA1A3930-0318-45CB-95EA-3DBD68930C74

P356

Q37900475-DC27EB7A-19FB-4C0B-9FDC-D06D75073CC7

P433

Q37900475-0F450C48-5004-41E5-8CD8-F35530304FCE

P478

Q37900475-2941C01B-8D0D-4D08-B5E6-A6E56ABAC5E6

P577

Q37900475-F3D03205-BDD9-481A-B0ED-64C422669B3B

P698

Q37900475-8502791F-5074-434A-8D18-080D5220042B

P921

Q37900475-0794E2AA-69A1-4E3C-A1CD-7BC4A70BD754

P356

NRENDO.2011.108

P1433

Nature Reviews Endocrinology

P1476

Parathyroid hormone analogues in the treatment of osteoporosis.

@en

P2093

Christian Meier

http://www.w3.org/2001/XMLSchema#string

Marius E Kraenzlin

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.

Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).

Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis

Harnessing the parathyroids to create stronger bones.

P2888

nrendo.2011.108

P304

647-656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRENDO.2011.108

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21750510

http://www.w3.org/2001/XMLSchema#string

P921